中国骨质疏松杂志
中國骨質疏鬆雜誌
중국골질소송잡지
CHINESE JOURNAL OF OSTEOPOROSIS
2014年
12期
1428-1431
,共4页
严坚强%孙奎%梁必如%池科德%吴俊哲%李大刚
嚴堅彊%孫奎%樑必如%池科德%吳俊哲%李大剛
엄견강%손규%량필여%지과덕%오준철%리대강
唑来膦酸%骨质疏松性椎体压缩骨折%经皮椎体成形术
唑來膦痠%骨質疏鬆性椎體壓縮骨摺%經皮椎體成形術
서래련산%골질소송성추체압축골절%경피추체성형술
Zoledronic acid%Osteoporotic vertebral compression fracture%Percutaneous vertebroplasty
目的:通过对比研究,观察骨质疏松性椎体压缩骨折的患者在经皮椎体成形术后应用唑来膦酸的临床治疗效果。方法2010年7月至2013年2月,将中山市中医院骨一科240例椎体压缩性骨折行PVP手术治疗的患者随机分成两组,治疗组在术后3日予以静滴唑来膦酸针;对照组单纯予以椎体成形术。两组患者自入院起均予以口服碳酸钙/维生素D3片,600 mg/d。分别于术前1周及术后1月、3月、6月、9月、一年行腰椎骨密度、血清PINP及β-CTX浓度检查,并进行统计分析。结果随访1年,两组患者共240例获得随访,治疗后治疗组患者在VAS评分、腰椎骨密度、血清PINP及β-CTX浓度等的变化与对照组相比均具有显著性差异,且治疗组患者的依从性较好,新发椎体骨折少。结论唑来膦酸治疗骨质疏松性椎体压缩骨折可增加患者椎体骨密度、改善患者疼痛、预防新发椎体骨折、提高患者生活质量,可用于骨质疏松性椎体压缩骨折患者PVP术后的巩固治疗。
目的:通過對比研究,觀察骨質疏鬆性椎體壓縮骨摺的患者在經皮椎體成形術後應用唑來膦痠的臨床治療效果。方法2010年7月至2013年2月,將中山市中醫院骨一科240例椎體壓縮性骨摺行PVP手術治療的患者隨機分成兩組,治療組在術後3日予以靜滴唑來膦痠針;對照組單純予以椎體成形術。兩組患者自入院起均予以口服碳痠鈣/維生素D3片,600 mg/d。分彆于術前1週及術後1月、3月、6月、9月、一年行腰椎骨密度、血清PINP及β-CTX濃度檢查,併進行統計分析。結果隨訪1年,兩組患者共240例穫得隨訪,治療後治療組患者在VAS評分、腰椎骨密度、血清PINP及β-CTX濃度等的變化與對照組相比均具有顯著性差異,且治療組患者的依從性較好,新髮椎體骨摺少。結論唑來膦痠治療骨質疏鬆性椎體壓縮骨摺可增加患者椎體骨密度、改善患者疼痛、預防新髮椎體骨摺、提高患者生活質量,可用于骨質疏鬆性椎體壓縮骨摺患者PVP術後的鞏固治療。
목적:통과대비연구,관찰골질소송성추체압축골절적환자재경피추체성형술후응용서래련산적림상치료효과。방법2010년7월지2013년2월,장중산시중의원골일과240례추체압축성골절행PVP수술치료적환자수궤분성량조,치료조재술후3일여이정적서래련산침;대조조단순여이추체성형술。량조환자자입원기균여이구복탄산개/유생소D3편,600 mg/d。분별우술전1주급술후1월、3월、6월、9월、일년행요추골밀도、혈청PINP급β-CTX농도검사,병진행통계분석。결과수방1년,량조환자공240례획득수방,치료후치료조환자재VAS평분、요추골밀도、혈청PINP급β-CTX농도등적변화여대조조상비균구유현저성차이,차치료조환자적의종성교호,신발추체골절소。결론서래련산치료골질소송성추체압축골절가증가환자추체골밀도、개선환자동통、예방신발추체골절、제고환자생활질량,가용우골질소송성추체압축골절환자PVP술후적공고치료。
Objective To observe the efficacy of zoledronic acid in the treatment of osteoporotic vertebral compression fracture ( OVCF) after percutaneous vertebroplasty ( PVP) .Methods Two hundred and forty OVCF patients treated with PVP from July 2010 to Feberary 2013 were randomly divided into 2 groups.The patients in the treatment group received intravenous 5 mg zoledronic acid once a year after 3 days of the operation.The patients in the control group received PVP only.The patients in both groups received oral vitamin D3 and caltrate daily.The VAS scores, BMD of the lumbar spine, PINP, and β-CTX were tested before and 1-, 3-, 6-, 9-, and 12-month after the operation.All the results were analyzed statistically.Results All the 240 patients in both groups were followed up for 1 year.Compared to those in the control group, the VAS scores, BMD of lumbar spine, PINP, andβ-CTX were significantly different to those in the control group.The patients in the treatment group had a better compliance and lower rate of new fractures of the vertebral body.Conclusion Zoledronic acid administration once a year can increase BMD, ruduce the pain and fracture risk, and improve the quality of life in OVCF patients.Zoledronic acid treatment should be used for OVCF patients after PVP operation.